Genetic Overlap and Causal Links Between Serum 25OHD Levels and Bone Mineral Density
Overview
This study reveals a shared genetic basis between serum 25-hydroxyvitamin D (25OHD) levels and bone mineral density (BMD), identifying specific pleiotropic loci and gene-tissue pairs. Mendelian randomization analyses indicate no overall causal effect of serum 25OHD on BMD in the general population but demonstrate positive causal effects in males and older individuals.
Background
Osteoporosis, characterized by low bone mineral density and deterioration of bone microarchitecture, affects a significant portion of the global population. Serum 25-hydroxyvitamin D (25OHD) is crucial for calcium homeostasis and bone remodeling, yet epidemiological studies have shown inconsistent associations between serum 25OHD levels and BMD. Previous Mendelian randomization studies have been limited by small sample sizes, lack of sex- and age-specific analyses, and insufficient adjustment for confounders such as body mass index. This study aims to clarify the genetic and causal relationships between serum 25OHD and BMD using large-scale genetic data and advanced statistical methods.
Data Highlights
Parameter
Value
95% CI
P-value
Global genetic correlation (rg)
-0.001
—
0.95
Local genetic signal at 5p11-5q11.9
Significant
—
—
2-sample MR overall causal effect (β)
0.003
-0.04 to 0.03
0.93
1-sample MR causal effect in males (β)
0.005
0.00 to 0.01
0.03
1-sample MR causal effect in older individuals (β)
0.009
0.00 to 0.02
0.01
Pleiotropic SNVs identified
49 total, including 4 novel SNVs
—
—
Gene-tissue pairs with overlap
95
—
—
Key Findings
No significant global genetic correlation between serum 25OHD levels and estimated heel BMD was observed (rg = -0.001; P = 0.95), but a significant local genetic signal was identified at chromosome region 5p11-5q11.9.
Two-sample Mendelian randomization showed no overall causal effect of serum 25OHD on BMD in the general population (β = 0.003; P = 0.93).
One-sample Mendelian randomization revealed positive causal effects of serum 25OHD on BMD in males (β = 0.005; P = 0.03) and individuals older than 65 years (β = 0.009; P = 0.01).
Forty-nine pleiotropic single-nucleotide variations (SNVs) were identified, including four novel SNVs (rs1077151, rs79873740, rs12150353, rs4760401), indicating shared genetic loci influencing both traits.
Ninety-five gene-tissue pairs showed overlap, predominantly enriched in nervous, digestive, exocrine/endocrine, and cardiovascular systems, suggesting complex biological pathways.
Protein-protein interaction analysis highlighted RPS9 and RPL7A as hub genes potentially involved in the shared genetic architecture.
Clinical Implications
These findings suggest that enhancing serum 25OHD levels may confer bone health benefits, particularly in men and older adults, potentially reducing osteoporosis risk. The identification of shared genetic loci and biological pathways provides a foundation for targeted interventions and personalized approaches to bone health management. Clinicians should consider sex and age when evaluating vitamin D supplementation strategies for osteoporosis prevention.
Conclusion
This comprehensive genetic analysis elucidates a shared genetic basis and age- and sex-specific causal links between serum 25OHD levels and bone mineral density. The results support the potential benefit of vitamin D optimization in reducing osteoporosis risk among specific populations.
References
Zhao et al. 2024 -- Genetic Overlap and Causal Links Between Serum 25-Hydroxyvitamin D Levels and Bone Mineral Density
